This clinical trial, sponsored by the Fondo Nacional de Desarrollo Científico y Tecnológico in Chile, investigates a steroid-free immunosuppression regimen in pediatric renal transplant patients. The potential success of this study could position the sponsor favorably in the pediatric transplant market, which is increasingly focused on minimizing steroid use due to associated growth and metabolic side effects. If the results demonstrate improved growth and bone metabolism without increased rejection rates, this could lead to a competitive advantage over existing steroid-based therapies. Additionally, the findings may attract interest from pharmaceutical companies looking to develop or enhance immunosuppressive therapies for pediatric patients, indicating potential partnership or acquisition opportunities.